• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Societal CDMO

    Syngene International Ltd.

    Federal Equipment Company

    Lannett CDMO

    Bachem
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Societal CDMO

    Syngene International Ltd.

    Federal Equipment Company

    Lannett CDMO

    Bachem
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Formulation Development Options to the Clinic

    Strategies for getting to Phase I quicker and saving API

    Paul Skultety, Ph.D.06.03.09

    Formulation Development Options to the Clinic



    Strategies for getting to Phase I quicker and saving API



    By Paul Skultety, Ph.D.



    Pharmaceutical companies are struggling to do more with less. Driven by pipeline productivity objectives and financial constraints, drug companies of all sizes are under pressure to reach critical milestones faster in spite of challenging molecular properties associated with their candidates, and with limited quantities of active pharmaceutical ingredient (API). The ability to work smarter has become a critical survival skill in order to move drug development candidates forward faster and to maximize the chance for success. Though not all are relevant for commercial scale, there are a host of formulation development options to consider that enable speed to first-in-human studies while conserving API and other resources. API in bottle, powder in bottle, API into capsule, and traditional formulations are all approaches worthy of consideration as possible formulation options for clinical supplies for a Phase I clinical trial. We shall explore considerations for prototype formulation development, formulation options for phase I studies, a prototype formulation approach, strategies to overcome poorly soluble compounds, liquid in capsule, and controlled release formulations.

    API Considerations for Formulation Development



    Provided the physical characteristics will not drastically change, formulation development projects may begin as soon as GLP-grade API is available. Most scientists understand the importance of setting chemical specifications and addressing chemical stability, but many fail to understand the benefit of assessing the physical characteristics and stability of their API early on. Solid state chemistry provides compound knowledge that helps maximize a drug development candidate’s chances for success and can help build and protect a sound intellectual property position. Chemical stability, sensitivity to moisture or light, pH solubility, polymorph identification, particle size, shape and distribution, flowability and physical stability: these are all important chemical and physical characteristics in API characterization. Once the dosage form approach — oral solid, oral liquid or parenteral — has been established, one needs to identify the appropriate technical leads for analytical and formulation development.

    Formulation Options for Phase I Studies



    For the oral dosing route of administration, there are four main dosage form options to consider for first-in-human studies.These are API in bottle, powder in bottle, API into capsule, and traditional formulation for tablets/capsules. All four options are utilized and each approach has associated advantages and disadvantages. These factors should be carefully considered prior to the selection of the appropriate option for each API.

    API in Bottle



    This approach is to directly weigh the API into the vial or bottle. This process eliminates the need for any excipients to be used, so there is no formulation development necessary. Analytical methods development is minimized as there is no need for additional methods work; the use of the API method is all that is needed. Stability is simplified, as there has been nothing added to the API and it is only in contact with the vial. This route minimizes the amount of API needed, as there is little loss of API in the manufacturing process, and it can support a wide range of dosage strengths; adding another strength simply requires changing the amount being weighed. In addition, due to the manufacturing process being only a weigh step, the physical characteristics of the API — such as poor flow or crystal structure — are not a problem.

    The right solution must be selected for use in the clinic in order to provide a solution of the API. Most often this is water, but if the drug does not have sufficient solubility, a suspension may be used. If a suspension is the dosage form of administration, it is recommended that a rinsing study be conducted to make sure all of the API is delivered in the clinic at the time of dosing. It is also advisable to do some stability work on the solution or suspension. The Phase I clinic site may intend that the dose will be administered shortly after it is made, however there may be a time when something comes up and the prep will sit for an hour or two or more. A short-term stability study on the solution or suspension will save a lot of headaches, should the phone call arrive indicating that a delay in dosing has occurred.

    Downfalls of this approach include additional clinic preparation time resulting from the need for someone to make the solution/suspension on-site, solubility limitations that may require large volumes of solution to be dosed or a suspension to be utilized, challenges associated with taste, patient inconvenience if the medication is taken home, and development of a matching placebo. One option for evaluating taste is using an electronic tongue, such as the Alpha M.O.S. Astree Electronic Tongue, which quantifies the bitterness of the API and assists in development of a suitable matching placebo for blinded clinical trials.

    Powder in Bottle



    Powder in bottle is a similar approach as API in a bottle that enables rapid progression into human clinical trials. This option supports a wide range of dosage strengths, eliminates API characteristics, does not require cleaning verification, and is a valid option for companies facing the challenge of limited API. When a bottle contains API and excipients, a minimum amount of developmental stability data are needed on both dry blend and reconstituted material. The advantage of this approach is that the possible bad taste may be masked by the addition of flavors to the powder blend.

    Disadvantages of this approach include longer manufacturing time, clinic preparation time, patient inconvenience if the medication is taken home, and matching placebo. In addition, content uniformity can be an issue depending on the powder blend characteristics. More analytical method development is required to support the content uniformity testing. Depending on how the blend is manufactured, cleaning verification might be needed.

    API into Capsule



    API into capsule programs are a third means to provide a fast, cost-effective path to Phase I studies, allowing greater flexibility in dosing for clinic without resulting loss in quality. Overall development timelines may be reduced by as much as six months, since eliminating the need for excipients results in decreased formulation development and stability testing. Accordingly, the API into capsule approach eliminates the need for content uniformity testing and in some cases dissolution testing, resulting in time savings from reduced analytical method development and formulation requirements. Finally, development of a matching placebo is very straightforward.


    Xcelodose® 600 S precision powder micro-dosing system. Photo courtesy of Capsugel

    For most APIs, API into a capsule can be accomplished very quickly using automated systems, such as Capsugel’s Xcelodose® 600 S precision powder micro-dosing system. These APIs do not require a flow-aiding excipient or physical processing step. This approach is flexible and can provide a wide range of strengths without a lot of additional API being necessary. The yield of usable capsules is usually very high. Depending on the automated encapsulation equipment being used, cleaning verification may or may not be required.

    This approach is suitable for both gelatin and hydroxy-propyl methylcellulose capsules, but compatibility of API with the capsule shell must be considered. Once the appropriate size and capsule type have been determined, lot release for clinical use is limited to one capsule type and API, and the creation of an approved batch record. It is important to stress that changes in the physical characteristics of the API should be kept to a minimum after the feasibility study, as this could alter the filling process on the encapsulation equipment.

    Formulated Tablet/Capsule



    Traditional formulation of solid oral dosage forms (tablets and capsules) may be initiated earlier, provided the chemical synthesis and physical representation of the API does not drastically change. The prototype approach for an oral solid tablet formulation starts with an excipient compatibility study as these provide a rational basis for identification of low risk excipients with physical and chemical compatibility to the API. A well constructed drug-excipient compatibility study typically involves between 15 and 20 excipients, and takes preformulation data, dosage strength, final dosage form, method of manufacturing, and animal study data into account, assigning a relative risk level to each excipient within a functional class.

    For this approach, adding additional strengths will require much larger amounts of API. It is best to determine the dose range up front to determine how much work can be done with the available amount of API. For tablets, it is necessary to decide if one wants to develop a common blend or to keep the tablet size the same to minimize the placebo work needed for possible blinding purposes. Batch size requirements for the prototype formulations are between 100 – 300 grams and approaches can vary among direct compression, roller compaction and wet granulation. Granulation has many advantages including improved powder flow, improved compressibility, reduced amount of fines, ability to modify the density, improved content uniformity, and lastly the ability to control the segregation of excipients. It is usually best to develop two or three prototype formulations using different formulation approaches and/or excipients and put them all up on prototype stability. This will help to ensure an acceptable formulation is ready for the start of the Phase I trial.

    Critical success factors for prototype formulation development vary by dosage strength. For a high dose (> 250 mg), critical API characteristics include flowability, compressability, and availability of material. For midrange doses (25 mg – 250 mg), critical characteristics include availability and flowability. For a low dose (< 25 mg), handling procedures and solution stability are API characteristics, in addition to concerns regarding content uniformity. Each prototype formulation is placed on stability in order to evaluate both physical and chemical characteristics over time. Criteria for the evaluation and selection of the optimal formulation includes ratio of excipients, flow characteristics, hardness versus force, particle size granulation and dissolution profile (pH dependency of release rate).

    There are two big advantages to this approach over the other three discussed. It is faster to start a Phase II trial with an acceptable dosage form that can be modified into a commercial formulation, and there is less concern about having to do a bridging study from the formula that was utilized in the Phase I study.

    The disadvantage of this approach is that it will take much longer to develop an acceptable formulation. There will be the cost of the additional analytical support for methods development, including a cleaning verification method and stability studies. Dissolution is now needed for release of the clinical supplies and for the stability testing. There will be less flexibility in providing different dosage strengths and the amount of needed API has increased several fold. Depending on the strength(s) being developed, content uniformity might be a concern. The particle size and shape of the API will potentially play a much bigger role in how robust the manufacturing process will be.

    Considerations for Manufacture of Phase I Clinical Supplies



    Once the optimal formulation approach is selected, it is time to develop the clinical manufacturing plan. Batch size requirements for a typical Phase I clinical supply range from 250g to 1kg of powder blend or API, depending on which formulation approach is carried forward. The goal is to end up with approximately 5,000 – 10,000 dosage units. This amount includes enough to handle retain samples, release testing and stability.

    For tablets and capsules, it is important that the selected formulation is robust enough to meet the in-process specifications for tablet hardness and be able to maintain the acceptable weight range. In addition, the formulation should be able to meet release specifications for dissolution, disintegration, assay and content uniformity.

    Overcoming Poor Solubility For Oral Solid Dosage Forms



    Over the past decade, formulators have faced unprecedented challenges with drugs of poor solubility. One-tenth of marketed drugs have solubility problems, more than one-third of drugs in the pipeline are poorly soluble, and nearly two-thirds of drugs from synthesis stage have low solubility [<0.1 mg/mL].1Conventional formulation and process strategies to overcome poor solubility have included the use of water soluble excipients, API micronization, pH modifiers, or solubilizing or wetting agents. Alternate processing approaches include the addition of an aqueous granulating solution which contains a wetting or solubilizing agent, using high shear homogenization to reduce the API to nanoparticles, potentially altering the API characteristics by dissolving API into hydroalcoholic/alcoholic granulating solutions, the formation of solid dispersion or hot melt extrusion, the use of complexing agents such as cyclodextrins, spray drying the API with wetting or solubilizing agents, or liquid fill into hard gelatin capsules.

    The “liquid filled in hard shell capsule” option eliminates poor flow, bad taste, concerns about content uniformity and physical characteristic concerns of the API. This removes the need for inclusion of a flow aid, sweetener or a flavorant in the formula. Relative to the traditional dosage formulation development process, these aspects present lesser challenges and decrease the time and API requirements, also eliminating the need for taste evaluation or a taste panel. In addition, the elimination of taste-matched placebo development for blinded clinical trials is a big advantage, and supports the time stringent nature of the projects. Capsugel’s CFS 1200 is one example of automated instrumentation that enables standard liquid filling using LiCaps® capsule and Liquid Encapsulation Microspray Sealing (LEMS®) technology2.

    When utilizing the liquid in capsule option, the foremost challenge is solubilizing the API in a favorable solvent system. The wide variety of marketed excipients forces formulators to understand the basic nature of the drug and to gain familiarity with the various excipients in order to make the optimal selection. Bioavailability enhancers are also available if needed. API considerations include dose requirements, melting point, drug substance stability, and excipient selection. For liquid filled capsules, corn oil, castor oil and sesame oil are recommended excipients. For semi-solids, gelucires and cremophor are proposed excipients.

    Controlled Release Formulations in Phase I



    A general approach for development of controlled release formulations involves identifying the desired product characteristics and estimation of dose range. This information can be used for defining the optimal dosage form (tablet, capsule or multiparticulate). There are a variety of controlled release systems for consideration: diffusion controlled, erodible, osmotic control and swelling. Pharmacokinetic considerations can be used for estimating the in vitro release rate (8- or 24-hour release).

    A typical sustained release development plan can include the development of several prototype formulations, which may include different release mechanisms. These should be placed on stability to evaluate them for any potential problems. Ideally at least three different release rates will be used in the Phase I study: the target release profile, and then one faster and one slower than the target. This will allow for the start of development of an in vitro/in vivo correlation.

    Companies are faced with a number of excellent options for possible formulation approaches to take into Phase I clinical studies.It is important to try to make the optimum formulation choice that will give the API the best chance of success. In addition, the most critical factors for development must be evaluated. There is no one right formulation approach that will fit every API. A company must evaluate the advantages and disadvantages of each approach to determine if it is the need to save time, save money, or conserve available API that will determine which option is the best for their compound.

    References

    1 T. E. Cole, “Liquid Filled and Sealed Hard Gelatin Capsules,” Capsugel Library (2000)

    2 Xcelodose and LEMS are registered trademarks of Capsugel
    Paul Skultety, Ph.D. is director, Pharmaceutical Development Services, at Xcelience, LLC, a provider of drug development and manufacturing solutions for virtual, specialty and large pharmaceutical companies. The author would like to acknowledge the help of Kim Black-Washington, whose assistance was invaluable in preparing the manuscript.
    Related Searches
    • Analytical Methods
    • Phase II
    • Manufacturing
    • Parenteral
    Suggested For You
    Trust, but Verify Trust, but Verify
    API Development Trends API Development Trends
    Raman Spectroscopy for Pharmaceutical Analysis & Quality Control Raman Spectroscopy for Pharmaceutical Analysis & Quality Control
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Outsourcing the Manufacture of Clinical Trial APIs Outsourcing the Manufacture of Clinical Trial APIs
    Inhaled Drug Delivery Trends Inhaled Drug Delivery Trends
    Maintaining Critical Drug Supply During COVID-19 Maintaining Critical Drug Supply During COVID-19
    Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond
    Choosing and Managing a CDMO Choosing and Managing a CDMO
    Global Outsourcing Trends Global Outsourcing Trends
    Medrio and Phastar Partner to Leverage Metadata for Advanced Data Visualization Medrio and Phastar Partner to Leverage Metadata for Advanced Data Visualization
    Bachem reports excellent results for the first half-year 2021 Bachem reports excellent results for the first half-year 2021
    Bachem and Novo Nordisk Redesign SPPS for Green Chemistry Bachem and Novo Nordisk Redesign SPPS for Green Chemistry
    Propofol – A Bachem Success Story Propofol – A Bachem Success Story
    Curia to Expand U.S. Commercial Manufacturing Capability Curia to Expand U.S. Commercial Manufacturing Capability

    Related Columns

    • Trust, but Verify

      Trust, but Verify

      Or, R.I.P, CoA.
      Emil W. Ciurczak, DoraMaxx Consulting 09.09.21

    • APIs | Drug Development
      API Development Trends

      API Development Trends

      Why is it important to consider solid form in API development?
      John Mykytiuk, Jamie Marshall and Andrew Blythe-Dickens, Sterling Pharma Solutions 09.09.21

    • Analytical Services | Laboratory Testing
      Raman Spectroscopy for Pharmaceutical Analysis & Quality Control

      Raman Spectroscopy for Pharmaceutical Analysis & Quality Control

      Raman spectroscopy helps ensure quality along the pharma supply chain of materials—from incoming raw materials through to finished product.
      Jacques Ledru, Head of Characterization, Catalent, Nottingham 09.09.21


    • APIs | Solid Dosage/Creams/Ointments
      Spray Drying: A Proven Approach to Enhance the Solubility of APIs

      Spray Drying: A Proven Approach to Enhance the Solubility of APIs

      Spray drying is an established particle engineering technology that offers several advantages over other methods used for improving API bioavailability.
      Benzion Dolitzky, PhD, VP R&D, Wavelength Pharmaceuticals 09.09.21

    • APIs | Clinical Trial Materials
      Outsourcing the Manufacture of Clinical Trial APIs

      Outsourcing the Manufacture of Clinical Trial APIs

      What to consider when deciding to partner with a CDMO for manufacturing.
      Josh Hoerner, General Manager, Purisys 09.09.21

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login